Chronic inflammation often precedes malignant transformation and later drives tumor progression. Likewise, subversion of the immune system plays a role in tumor progression, with tumoral immune escape now well recognized as a crucial hallmark of cancer. Myeloid-derived suppressor cells (MDSC) are elevated in most individuals with cancer, where their accumulation and suppressive activity are driven by inflammation. Thus, MDSC may define an element of the pathogenic inflammatory processes that driven immune escape. The secreted alarmin HMGB1 is a pro-inflammatory partner, inducer and chaperone for many pro-inflammatory molecules that MDSC development. Therefore, in this study we examined HMGB1 as a potential regulator of MDSC. In murine tumor systems, HMGB1 was ubiquitous in the tumor microenvironment, activating the NF-ʃB signal transduction pathway in MDSC and regulating their quantity and quality. We found that HMGB1 foments the development of MDSC from bone marrow progenitor cells, contributing to their ability to suppress antigen-driven activation of CD4+ and CD8+ T cells. Further, HMGB1 increased MDSC-mediated production of IL-10, enhanced crosstalk between MDSC and macrophages and facilitated the ability of MDSC to down-regulate expression of the naive T cell homing receptor L-selectin. Overall, our results revealed a pivotal role for HMGB1 in the development and cancerous contributions of MDSC in cancer patients.
Introduction
Anti-tumor immunity and immunotherapies that activate innate and/or adaptive immunity have potential for the prevention and/or treatment of primary and metastatic cancers. However, immunotherapies are frequently ineffective because cancer patients contain immunosuppressive cells. Myeloid-derived suppressor cells (MDSC) (1) are present in virtually all patients with solid tumors and are major contributors to immune suppression. They facilitate tumor progression through multiple immune mechanisms including the inhibition of T and NK cell activation (2) , polarization of immunity towards a tumor-promoting type 2 phenotype through their production of IL-10 (3), and by perturbing the trafficking of naïve T cells by down-regulating L-selectin (4) . MDSC also use non-immune mechanisms to enhance tumor growth. They produce VEGF and matrix metalloproteases that promote tumor vascularization (5) as well as invasion and metastasis (6) .
Chronic inflammation has long been associated with tumor onset and progression (7) .
The role of chronic inflammation was originally attributed to its ability to foster genetic mutations, enhance tumor cell proliferation and survival, and promote metastases. Chronic inflammation also facilitates malignancy by inducing the accumulation and increasing the potency of MDSC, which prevent adaptive and innate immunity from delaying tumor progression (8) . Multiple redundant pro-inflammatory molecules drive MDSC. Since the Damage Associated Molecular Pattern molecule (DAMP) and alarmin High Mobility Group Box Protein I (HMGB1) is pro-inflammatory and is a binding partner, inducer, and/or chaperone for many of the pro-inflammatory molecules that drive MDSC (9), we have studied HMGB1 as a potential regulator of MDSC. HMGB1 was originally identified as a DNA binding protein in the nucleus. It performs multiple functions within the nucleus including changing the conformation of DNA to allow for the binding of regulatory proteins, facilitating the integration of transposons into DNA, and stabilizing nucleosome formation (10) . Its role as a secreted protein and an immune modulator has only been recognized within the past 15 years (11) .
We now report that in addition to many other cells, MDSC release HMGB1 and that HMGB1 activates MDSC through NF-ʃB and facilitates several immune suppressive mechanisms used by MDSC to inhibit anti-tumor immunity. HMGB1 drives the differentiation of MDSC from bone marrow progenitor cells, enhances crosstalk between MDSC and macrophages by increasing MDSC production of IL-10, and reduces the expression of L-selectin on circulating T cells. Collectively, these results suggest that HMGB1 contributes to immune suppression by inducing and activating MDSC.
Materials and Methods
Mice. BALB/c, C57BL/6, BALB/c IL-10 -/-, BALB/c TLR4 -/-, BALB/c DO11.10 (TCR-transgenic for the ɲɴ-TCR specific for OVA peptide 323-339 restricted by I-A d ) and BALB/c clone 4 TCR-transgenic (ɲɴ-TCR specific for influenza hemagglutinin 518-526 restricted by H-2K d ) mice were from The Jackson Laboratory (Bar Harbor, ME) and/or bred in the UMBC animal facility. Mice <6 months of age were used for all experiments. All animal procedures were approved by the UMBC IACUC.
Reagents and antibodies.
Heparin sodium salt (grade IA) and ethyl pyruvate were from SigmaAldrich. Glycyrrhizin (ammonium salt) was from Calbiochem. Recombinant mouse IL-6 and GM-CSF were from Biolegend. Recombinant mouse IFN-ɶ, HMGB1, and TNFɲ were from R&D Systems. Recombinant LPS was from Difco. mAbs Gr1-APC-Cy7, Gr1-APC (RB6-8C5), CD45-PE (30-F11), CD8-FITC (53-6.7), CD4-PE (L3T4/GK1.5), CD3-PE-Cy7 (145-2C11), CD11b-PE (M1/70), CD11c-FITC (HL3), CD45R-B220-PE (RA3-6B2), CD62L-APC (MEL14), c-kit-PE (CD117; ACK45), iNOS, arginase, rat IgG2b isotype, and annexin V were from BD Biosciences. T cell activation assays. T cell activation assays were performed as described (17) Membranes were blocked with 5% milk in TBST. HMGB1 was detected with anti-HMGB1 antibody (Epitomics) (5ng/ml in 10ml of 2.5% milk/TBST) followed by goat-anti-rabbit-HRP (Millipore) (40ng/ml in 10ml of 2.5% milk/TBST). Protein was visualized using an HRP detection kit (Denville Scientific, Inc). HMGB1 levels were measured by ELISA according to the manufacturer's directions (IBL International, Hamburg, Germany). Flow cytometry. Cells were labeled and analyzed by flow cytometry for cell surface molecules as described (17) . For bone marrow experiments, cells were first stained using the LIVE/DEAD fixable yellow dead cell stain kit (Invitrogen) per the manufacture's protocol, followed by staining for cell surface markers with antibodies diluted in PBS/ 2% FCS (HyClone). For NF-ʃB staining of MDSC, 3x10 6 -5x10 6 leukocytes/ml RPMI were incubated with/without 50 ng/ml HMGB1 for 15 minutes at 37 o C, fixed and permeabilized and then stained with rabbit mAb phospho-NF-ʃB p65 (Ser536; clone 93H1) and goat-anti-rabbit (Fab') 2 -AlexaFluor 647 (Cell Signaling, Inc.) according to the manufacturer's protocol, followed by staining for Gr1 and CD11b. Peritoneal macrophages (5x10 6 /5 ml DMEM) were similarly stained, except they were rested for 2 hrs at 37°C before stimulation with 20ng/ml TNFɲ or 100ug/ml LPS, and subsequently incubated with Fc block (CD16/32) for 15 min., followed by staining with NF-ʃB, CD11b, and F4/80 mAbs. For ADAM17 staining, 3x10 6 -5x10 6 leukocytes were incubated with or without HMGB1 (50 ng/ml) or ethyl pyruvate (10mM) for zero, two, and four hours and stained with mAb to ADAM17. For tumor-infiltrating MDSC, solid tumors were prepared as they were for tumor supernatants, except collagenase (300 U/ml) was included in the dissociation medium, and the resulting cells were centrifuged through ficoll to remove dead cells. Samples were run on a Cyan ADP flow cytometer and analyzed using Summit Software (Beckman/Coulter). statistical significance between two sets of data. Single-factor ANOVA was used to determine statistical significance between groups of data. Table 1 ).
Results

HMGB1 is ubiquitously
Since MDSC are driven by inflammation and themselves produce pro-inflammatory mediators (8, 20) , we tested MDSC for secretion of HMGB1. MDSC generated in 4T1 tumorbearing BALB/c mice were harvested from the blood, stained for Gr1 and CD11b, and assessed for their ability to suppress T cell activation (Fig. 1B) . Greater than 90% of the blood leukocytes were CD11b + Gr1 + and they were suppressive. We then tested MDSC for their ability to secrete HMGB1 by culturing them overnight and assaying the supernatant for HMGB1 by western blot and ELISA ( + cells gated and analyzed for pNF-ʃB (Fig. 1D) . HMGB1-treatment caused phosphorylation of NF-ʃB.
To confirm the specificity of the pNF-ʃB staining, macrophages from either TLR4 Fig. S1 ).
These data indicate that HMGB1 is ubiquitously present in vivo in the tumor microenvironment, multiple cell populations within the tumor microenvironment produce HMGB1, MDSC contribute to the production of HMGB1, and HMGB1 activates the NF-ʃB signal transduction pathway in MDSC. and macrophages by blocking NF-ʃB signaling (26) . Glycyrrhizin prevents the binding of extracellular HMGB1 by attaching to two distinct regions of HMGB1 (27) . At the end of the four day culture period, the presence of HMGB1 was confirmed by western blot ( Fig. 2A) (Fig. 2D) . Glycyrrhizin and ethyl pyruvate also decreased the generation of DC (Fig. 2E, Supplementary Fig. S2A ). Ethyl pyruvate reduced the level of progenitor cells but did not induce apoptosis as compared to vehicle treatment. These data indicate that HMGB1
facilitates the expansion of myeloid cells, including MDSC, from bone marrow progenitor cells. 
for their ability to prevent the proliferation of transgenic CD4 + (DO11.10) or CD8 + (Clone 4) T cells activated with cognate peptides (Fig. 3A) . Increasing concentrations of the HMGB1 inhibitor ethyl pyruvate restored T cell activation in the presence of MDSC. Since ethyl pyruvate prevents signaling through NF-ʃB and T cell activation requires NF-ʃB signaling (31), transgenic T cells were treated with ethyl pyruvate to ascertain that these doses were not affecting T cell proliferation (Fig. 3B) . Ethyl pyruvate did not increase T cell activation in the absence of MDSC, demonstrating that the increase in T cell activation seen in fig. 3A is an effect of ethyl pyruvate on MDSC and not an effect on T cells.
To determine how ethyl pyruvate inhibits MDSC, control and ethyl pyruvate-treated MDSC were assayed by flow cytometry for their content of molecules that mediate T cell suppression (arginase, iNOS, and H 2 O 2 ), and for its impact on MDSC viability. Ethyl pyruvate did not decrease arginase or iNOS levels or alter MDSC apoptosis levels ( Supplementary Fig.   S2B , S2C), but modestly reduced H 2 O 2 levels (Supplementary Fig. S2D ) as compared to vehicletreated cells. In previous studies, another NF-ʃB inhibitor, Withaferin A, also reduced the suppressive potency of MDSC (19) . These results suggest that HMGB1 contributes to MDSC- Fig. S2C ). These findings indicate that HMGB1 regulates MDSC production of IL-10 and macrophage-induced increases in MDSC production of IL-10.
MDSC also promote a type 2 immune response by down-regulating macrophage production of IL-12 (3) and IL-6 (unpublished). To determine if HMGB1 mediates either of these effects, MDSC and macrophages were co-cultured with or without ethyl pyruvate and glycyrrhizin and IL-12 and IL-6 were quantified by ELISA (Fig. 5) . Ethyl pyruvate and glycyrrhizin reduced macrophage production of IL-12 and IL-6, and did not restore production of these cytokines in MDSC-macrophage co-cultures. IL-1ɴ, a pro-inflammatory cytokine that is produced by MDSC and also drives the suppressive potency of MDSC (33, 34), was also assessed. Ethyl pyruvate and glycyrrhizin decreased MDSC production of IL-1ɴ; however, however it is not involved in MDSC-mediated down-regulation of macrophage-produced IL-12 or IL-6.
Neutralization of HMGB1 delays tumor growth and reduces MDSC in tumor-bearing mice.
HMGB1 includes two functional domains: the pro-inflammatory B Box and the antiinflammatory A Box. The B Box is a RAGE agonist, while the A Box is a RAGE antagonist (13) .
Although the A Box is a competitor for the B Box, the B Box of HMGB1 is dominant in vivo (27) .
However, if administered in vivo as a recombinant protein, A Box neutralizes endogenous HMGB1 (14) . To determine if A Box impacts tumor progression, BALB/c and C57BL/6 mice bearing 4T1 or MC38 tumor, respectively, were treated with A Box or vehicle control starting when the tumors were first palpable (approximate day 7-9 after tumor cell inoculation) ( Fig. S3A ). The effect of HMGB1 on spontaneous metastatic disease was assessed by treating 4T1 tumor-bearing mice with glycyrrhizin and ethyl pyruvate and assessing the number of metastatic cells by clonogenic assay (35) (Supplementary Fig. S3B ). 4T1/575 tumor-bearing mice survived significantly longer than mice with 4T1/irrelevant cells supporting previously published work (36) were not statistically significantly different. These results further confirm that HMGB1 enhances tumor progression.
To determine if HMGB1 drives MDSC accumulation in vivo, tumor-bearing mice were treated with a neutralizing HMGB1 mAb (2G7), and tumor-infiltrating MDSC and MDSC from the blood and spleen were compared to MDSC in vehicle-treated tumor-bearing mice. C57BL/6 mice were inoculated with the MC38 tumor on day 1 and 2G7 treatment was started on day 10-13. Mice were sacrificed at a late stage of disease when their primary tumors were approximately the same diameter, and total MDSC, monocytic MDSC, and granulocytic MDSC levels in the blood, spleen, and infiltrating the tumors were determined by flow cytometry (Fig.   6B) . Total, monocytic, and granulocytic MDSC were reduced in the spleens, blood, and tumors of 2G7-treated mice with the exception of tumor-infiltrating granulocytic MDSC. These decreases were not a secondary effect of reduced tumor size since, at the time of analysis, the 2G7-treated and control-treated mice had similar-sized primary tumors. MDSC were similarly reduced in the blood of A Box-treated tumor-bearing mice. These results indicate that in vivo, neutralization of HMGB1 reduces the accumulation of MDSC in tumor-bearing mice.
Tumors from the HMGB1 mAb-treated (2G7) and isotype control-treated mice of Fig. 6 were assessed by immunohistochemistry for the presence of CD3 + T cells (Supplementary Fig.   4 ). Both types of tumors contained few T cells; however, there was a trend towards more CD3 
Discussion
The DAMP and alarmin HMGB1 is released by many tumor cells, is elevated in the serum of many cancer patients (37) , and is recognized as an enhancer of tumor progression by its direct action on tumor cells (9, 10, 28) HMGB1 is likely to activate and drive MDSC because it induces, chaperones, and/or enhances the activity of several pro-inflammatory molecules that regulate MDSC. For example, IL-1ɴ drives MDSC accumulation and T cell suppressive activity (33, 38) and is induced by HMGB1 (14) . Complexes of HMGB1 and IL-1ɴ have increased pro-inflammatory activity relative to either molecule alone (39) . HMGB1 also enhances the pro-inflammatory activity of IL-6 (40), TNFɲ (14) , and prostaglandin E2 (41), three other pro-inflammatory mediators that drive MDSC (24, 34, 42, 43) . Although neutralization of HMGB1 significantly down-regulates MDSC suppressive activity, it does not globally neutralize MDSC, most likely because the multiple proinflammatory mediators that drive MDSC are redundant and can also be regulated by molecules 
